(149 days)
Not Found
No
The document describes a mechanical implant for ankle replacement and does not mention any software, algorithms, or data processing that would suggest the use of AI or ML.
Yes
The device is intended to reduce pain, restore alignment, and replace movement in damaged ankle joints, which directly aligns with the definition of a therapeutic device.
No
Explanation: The device, the INBONE™ Total Ankle, is described as an implantable prosthetic device intended to restore mobility and reduce pain in patients with damaged ankle joints. It is a treatment device, not a diagnostic one.
No
The device description clearly states it consists of physical components (tibial trays, talar domes, tibial inserts) made of materials like titanium alloy, cobalt-chrome, and UHMWPE. This indicates it is a hardware medical device, not software-only.
Based on the provided information, the INBONE™ Total Ankle is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use clearly states that the device is an implantable prosthesis designed to replace the ankle joint and restore mobility. This is a therapeutic and structural function within the body.
- Device Description: The description details the materials and components of an artificial ankle joint, which are surgically implanted.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
IVD devices are used outside the body to analyze samples and provide diagnostic information. The INBONE™ Total Ankle is an implantable medical device used within the body for treatment and structural support.
N/A
Intended Use / Indications for Use
Intended Use
The INBONE™ Total Ankle is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion movement in the ankle ioint.
Indications for Use
The INBONE™ Total Ankle is indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The INBONE™ Total Ankle is additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
Product codes
HSN
Device Description
The INBONE™ II Total Ankle System consists of tibial trays, talar domes and tibial inserts. The tibial trays and talar domes have modular stem connections. The tibial trays are manufactured from titanium alloy; the talar domes are manufactured from cobaltchrome; and the tibial inserts are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE). The INBONE™ II Total Ankle System is compatible with the predicate INBONE™ Total Ankle System components.
The INBONE™ II Total Ankle System is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
ankle joint
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Substantial equivalence was shown through stability and contact area testing. The results of the test show that the subject INBONE™ II Total Ankle System can be expected to perform at least as well as the legally marketed predicate INBONE™ Total Ankle.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3110 Ankle joint metal/polymer semi-constrained cemented prosthesis.
(a)
Identification. An ankle joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace an ankle joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces and has no linkage across-the-joint. This generic type of device includes prostheses that have a talar resurfacing component made of alloys, such as cobalt-chromium-molybdenum, and a tibial resurfacing component made of ultra-high molecular weight polyethylene and is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.
0
$\frac{1}{2}$
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
AUG 2 6 2010
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807.92, this information serves as a Summary of Safety and Effectiveness for the INBONE™ II Total Ankle System..
A.1. Submitted By: | Wright Medical Technology, Inc. |
---|---|
5677 Airline Rd | |
Arlington, TN 38002 | |
Date: | March 18, 2010 |
Contact Person: | Kelsey Lee |
Regulatory Affairs Specialist I | |
(901) 290-5909 |
A.2. Proprietary Name: | INBONE™ II Total Ankle System |
---|---|
Common Name: | Ankle Prosthesis |
Device Classification Regulation: | 21 CFR 888.3110--Class II |
Device Product Code & Panel: | HSN: Ankle joint metal/polymer semi-constrained cemented prosthesis |
87 Orthopedics |
A.3. Predicate Device: | INBONETM Total Ankle System (K051023) |
---|---|
------------------------ | --------------------------------------- |
A.4. Device Description
The INBONE™ II Total Ankle System consists of tibial trays, talar domes and tibial inserts. The tibial trays and talar domes have modular stem connections. The tibial trays are manufactured from titanium alloy; the talar domes are manufactured from cobaltchrome; and the tibial inserts are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE). The INBONE™ II Total Ankle System is compatible with the predicate INBONE™ Total Ankle System components.
The INBONE™ II Total Ankle System is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint.
The design features of the INBONE™ II Total Ankle System are substantially equivalent to the design features of other devices previously cleared for market.
1
A.S. Intended Use
The INBONE™ Total Ankle is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion movement in the ankle ioint.
Indications for Use
The INBONE™ Total Ankle is indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The INBONE™ Total Ankle is additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
The indications are similar to the legally marketed predicate device.
A.6. Technological Characteristics Comparison
The INBONE™ II Total Ankle System and the legally marketed predicate INBONE™ Total Ankle System have similar indications, utilize the same instruments, and are manufactured out of the same materials. The INBONE™ II Total Ankle System is also compatible with components from the legally marketed predicate INBONE™ Total Ankle System.
The INBONE™ II Total Ankle System differs from the legally marketed predicate in articulating surface geometry and additional stability in the talar dome.
B.1. Substantial Equivalence - Non-Clinical Evidence
Substantial equivalence was shown through stability and contact area testing. The results of the test show that the subject INBONE™ II Total Ankle System can be expected to perform at least as well as the legally marketed predicate INBONE™ Total Ankle.
The safety and effectiveness of the INBONE™ II Total Ankle System is adequately supported by the substantial equivalence information, materials information, and comparison of design characteristics provided within the Premarket Notification.
B.2. Substantial Equivalence - Clinical Evidence
N/A
B.3. Substantial Equivalence - Conclusions
Substantial equivalence is shown through stability testing and contact area testing. The materials are identical and the indications are similar and the subject and predicate differ in articulating surface geometry and additional talar dome stability, but no new types of safety and effectiveness questions can be expected. From the evidence given in the Premarket Notification, the subject devices can be expected to perform at least as well as the predicate devices.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Wright Medical Technologies, Inc. % Ms. Kelsey Lee 5677 Airline Road Arlington, TN 38002
AUG 2 6 2010
Re: K100886
Trade/Device Name: INBONE II Total Ankle System Regulation Number: 21 CFR 888.3110 Regulation Name: Ankle joint metal/polymer semi-constrained cemented prosthesis Regulatory Class: II Product Code: HSN Dated: August 16, 2010 Received: August 17, 2010
Dear Ms. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act that I DA has made a determination administered by other Federal agencies. You must of any I catal satures and regaranents ancluding, but not limited to: registration and listing (21 comply with an the rec- requirements, missions and so
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical Cr K F at 607), adeinig (21 OFR 803); good manufacturing practice requirements as set device-related adverse events) (21 OFF Part 820); and if applicable, the electronic a form in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Ms. Kelsey Lee
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Barbara Briehl
Mark N. Melk Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K 100 & 8 6
Device Name: INBONE™ II Total Ankle System
The INBONE™ Total Ankle is indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The INBONE™ Total Ankle is additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
1 of 1
Omtu for nxm
(Division Sign-Off)
Division Sign Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K100886